Old Mission Investment Co LLC Acquires Shares of 7,291 AbbVie Inc. $ABBV

Key Points

• Old Mission Investment Co. LLC acquired 7,291 AbbVie shares worth approximately $1.84 million in the second quarter. Institutional investors collectively own 70.23% of the company.
• AbbVie reported quarterly EPS of $3.65, exceeding estimates, while revenue rose 10.2% year over year to $16.99 billion. Shares opened at $255, near their 52-week high, and analysts maintain a “Moderate Buy” consensus with an average price target of $276.64.
• The company paid a quarterly dividend of $1.73 per share, equivalent to a 2.7% annualized yield. Separately, Executive Vice President Nicholas Donoghoe sold 32,710 shares for approximately $8.18 million.

Old Mission Investment Co LLC acquired a new stake in AbbVie Inc. (NYSE:ABBV - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 7,291 shares of the company's stock, valued at approximately $1,835,000.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. OceanIQ Capital LLC acquired a new position in AbbVie in the 2nd quarter valued at about $2,148,000. Highland Investment Advisors LLC acquired a new stake in AbbVie during the second quarter worth approximately $483,000. Outlook Capital Management LLC acquired a new stake in AbbVie during the second quarter worth approximately $74,000. Strive Financial Group LLC boosted its holdings in shares of AbbVie by 192.1% during the second quarter. Strive Financial Group LLC now owns 2,182 shares of the company's stock worth $549,000 after acquiring an additional 1,435 shares during the period. Finally, Munich Reinsurance Co Stock Corp in Munich boosted its holdings in shares of AbbVie by 3.8% during the second quarter. Munich Reinsurance Co Stock Corp in Munich now owns 157,348 shares of the company's stock worth $39,595,000 after acquiring an additional 5,727 shares during the period. Institutional investors own 70.23% of the company's stock.

Insider Activity

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the business's stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the transaction, the executive vice president owned 74,430 shares of the company's stock, valued at approximately $18,607,500. The trade was a 30.53% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.06% of the company's stock.

AbbVie Trading Up 1.6%

Shares of AbbVie stock opened at $255.00 on Friday. The company has a 50 day moving average of $254.54 and a 200-day moving average of $230.76. AbbVie Inc. has a 1-year low of $190.75 and a 1-year high of $267.47. The company has a market cap of $450.52 billion, a PE ratio of 72.03, a price-to-earnings-growth ratio of 1.13 and a beta of 0.29.

AbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.61 by $0.04. The business had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The firm's revenue for the quarter was up 10.2% on a year-over-year basis. During the same quarter last year, the business posted $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Research analysts forecast that AbbVie Inc. will post 14.05 earnings per share for the current year.

AbbVie Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend was Wednesday, July 15th. AbbVie's dividend payout ratio (DPR) is currently 195.48%.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Qulipta migraine expansion: AbbVie reported positive Phase 3 LUNA results for atogepant (Qulipta) in preventing menstrual migraine. The treatment met its primary and secondary endpoints, potentially opening a new indication and supporting intermittent use rather than continuous daily dosing. This could expand Qulipta’s commercial opportunity and reinforce AbbVie’s position in migraine care. AbbVie's migraine treatment meets late-stage study goal
• Positive Sentiment: Higher HSBC valuation: HSBC raised its price target for AbbVie to $315 from $300 while maintaining a Buy rating, signaling continued confidence in the company’s growth outlook and product pipeline. HSBC adjusts price target on AbbVie
• Positive Sentiment: Dividend maintained: AbbVie declared a quarterly cash dividend of $1.73 per share, payable Nov. 16 to shareholders of record Oct. 15. The unchanged payout supports the stock’s income appeal and reflects continued shareholder-return capacity. AbbVie declares quarterly dividend
• Neutral Sentiment: Pipeline and portfolio developments: Coverage highlighted the growth of Skyrizi and Rinvoq, the planned $10.9 billion Apogee Therapeutics acquisition, an ADARx collaboration and updated real-world data from an eye-implant study. These initiatives may diversify future growth, but their financial impact remains dependent on execution, approvals and clinical outcomes.
• Negative Sentiment: Regulatory setback: The FDA issued a Complete Response Letter for trenibotE, AbbVie’s fast-acting neurotoxin candidate. The action may delay the product’s launch and add uncertainty around the aesthetics pipeline. FDA issues Complete Response Letter for AbbVie’s trenibotE
• Negative Sentiment: Concentration and valuation concerns: Analysts continue to monitor AbbVie’s reliance on Skyrizi and the long-term effects of Humira’s patent-related decline. With the stock trading at a relatively elevated earnings multiple, execution risks and slower-than-expected diversification could limit further upside.

Analysts Set New Price Targets

ABBV has been the topic of a number of recent research reports. Weiss Ratings upgraded AbbVie from a "hold (c)" rating to a "buy (b-)" rating in a research note on Tuesday, August 4th. Evercore set a $235.00 price target on AbbVie in a research note on Friday, May 15th. Barclays upped their price objective on AbbVie from $275.00 to $300.00 and gave the company an "overweight" rating in a report on Wednesday, July 29th. Wall Street Zen downgraded AbbVie from a "strong-buy" rating to a "buy" rating in a report on Sunday, July 5th. Finally, Canaccord Genuity Group boosted their target price on shares of AbbVie from $282.00 to $290.00 and gave the company a "buy" rating in a research report on Monday, August 3rd. Two research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $276.64.

AbbVie Company Profile

AbbVie Inc NYSE: ABBV is a global biopharmaceutical company that discovers, develops and commercializes medicines across immunology, oncology, neuroscience, eye care, aesthetics and other specialty areas. The company was established in 2013 after separating from Abbott Laboratories, which retained Abbott's diversified medical products and diagnostics businesses while AbbVie focused on research-based pharmaceuticals.

AbbVie's immunology portfolio includes Skyrizi (risankizumab) and Rinvoq (upadacitinib), which are used to treat several inflammatory conditions.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.